ALSF is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The Babich Family Foundation (runx1.com) is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloid leukemia (AML) due to germline RUNX1 mutations with the ultimate goal of developing effective therapies to prevent the onset of AML.
ALSF and The Babich Family Foundation have partnered to raise awareness and accelerate research around familial RUNX1 disorders by creating two grant categories:
Familial RUNX1 Research Grant: Up to $250,000 over two years
Research leading to the prevention of the transition from pre-leukemia to leukemia for patients with the familial RUNX1 disorder.
Familial RUNX1 Patient Samples Grant: Between $250,000 & $500,000 over two years
To increase understanding of familial RUNX1 disorders through retrospective and/or prospective analyses of patient samples and outcome data.
The Program possesses a long-term perspective and aims to have subsequent grants build upon the research from the early grants. We are especially interested in innovative and cross-disciplinary approaches to developing therapies to prevent the onset of AML in pre-leukemia patients with the germline RUNX1 mutation.
The Familial RUNX1 Research Program application cycle is closed at this time. To be added to our notification list for the next RFA, please email [email protected]